FDA approval expands patient access to therapies for ACCORD.
Steady: 0 in the last 7 days
Updated oct 12
The latest in this situation
How it started
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA approval expands patient access to therapies for ACCORD.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Accord BioPharma launched its drug FILKRI in the U.S. following FDA approval in January 2026.Sub-event
FDA granted approval, expanding patient access to therapies for ACCORD.1 source
Keep exploring
The entities involved
Related events
- Discussion on the limits of pharmacotherapy and the role of FDA approvals.
- FDA placed a clinical hold on the drug application submitted by Bright Minds Biosciences Inc.
- ADC Therapeutics received accelerated approval for its drug from the FDA.
- The FDA is a U.S. government agency, a basic descriptive fact about the regulator.
- FDA approval coincided with Donald Trump's press conference on November 11, 2026.